Physician profile
Michael L Noble
NPI 1205931565
$592.61
in general payments reported to CMS, 2019-2025
13 companies · $19.48 in 2025
The $19.48 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2022: $35.55 · 2024: $13.91 · 2025: $19.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.48 · Entertainment: $13.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.48 |
| Entertainment | $13.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $191.12 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $78.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $64.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $54.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.43 | 2019 | |
| Pfizer INC. | $19.79 | 2022 | |
| Seqirus USA INC | $18.55 | 2019 | |
| Aytu Biopharma, INC. | $15.15 | 2019 | |
| Optos, INC. | $13.91 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $13.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Noble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.